Patient preferences for treatments to delay bone metastases

Prostate

Volumn 74, Issue 15, 2014, Pages 1488-1497

  Hauber, A Brett ^a   Arellano, Jorge ^b   Qian, Yi ^b   González, Juan Marcos ^a   Posner, Joshua D ^a   Mohamed, Ateesha F ^a   Gatta, Francesca ^b   Tombal, Bertrand ^c   Body, Jean Jacques ^d  

^a RTI HEALTH SOLUTIONS   (United States)

^b AMGEN INC   (United States)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Bone pain; Discrete choice experiment; Osteonecrosis of the jaw (ONJ); Prostate cancer; Skeletal related events (Sres); Time tradeoff

Indexed keywords

ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; FRACTURE; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PATIENT PREFERENCE; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; RISK FACTOR; SWEDEN; UNITED KINGDOM; BONE NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS; PSYCHOLOGY; QUESTIONNAIRE; SECONDARY; STATISTICAL MODEL; TREATMENT OUTCOME; VERY ELDERLY;

ANTINEOPLASTIC AGENT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; GREAT BRITAIN; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT PREFERENCE; PROSTATIC NEOPLASMS; QUESTIONNAIRES; SWEDEN; TREATMENT OUTCOME;

EID: 84924295247     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22865     Document Type: Article

References (26)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer-Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer 2013. Available from: http://globocan.iarc.fr/ Accessed on 30 January 2014.
2. Amaral TM, Macedo D, Fernandes I, Costa L. Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer 2012;2012:327253.
3. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-244.
4. Clines GA, Guise TA. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008;10:e7.
5. Lamothe F, Kovi J, Heshmat MY, Green EJ. Dissemination of prostatic carcinoma: an autopsy study. J Natl Med Assoc 1986;78:1083-1086.
6. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-583.
7. Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, Qian J, Steinberg J, Carducci M. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormonerefractory prostate cancer. Cancer 2008;113:2478-2487.
8. Sartor O, Eisenberger M, Kattan MW, Tombal B, Lecouvet F. Unmet needs in the prediction and detection of metastases in prostate cancer. Oncologist 2013;18:549-557.
9. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, ShoreN, Rader M, Wang H, JiangQ, Tadros S,Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-822.
10. Hoffman-Censits J, Fu M. Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer? Semin Oncol 2013;40:361-374.
11. MacVicar GR, Hussain MH. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer. Curr Opin Oncol 2013;25:252-260.
12. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gomez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379:39-46.
13. Summary Minutes of the FDA Oncologic Drugs Advisory Committee Meeting, September 14, 2011. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm235829.htm, Accessed on 30 January 2014.
14. de Bekker-Grob EW, Bliemer MC, Donkers B, Essink-Bot ML, Korfage IJ, Roobol MJ, Bangma CH, Steyerberg EW. Patients' and urologists' preferences for prostate cancer treatment: a discrete choice experiment. Br J Cancer 2013;109:633-640.
15. Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, Johnson FR. Conjoint analysis applications in health - how are studies being designed and reported?: an update on current practice in the published literature between 2005 and 2008. Patient 2010;3:249-256.
16. Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J. Conjoint analysis applications in health-a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 2011;14:403-413.
17. Blinman P, King M, Norman R, Viney R, Stockler MR. Preferences for cancer treatments: an overview of methods and applications in oncology. Ann Oncol 2012;23:1104-1110.
18. Hauber AB, Arden NK, Mohamed AF, Johnson FR, Peloso PM, Watson DJ, Mavros P, Gammaitoni A, Sen SS, Taylor SD. A discrete-choice experiment of United Kingdom patients' willingness to risk adverse events for improved function and pain control in osteoarthritis. Osteoarthritis Cartilage 2013;21:289-297.
19. Mohamed AF, Hauber AB, Neary MP. Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics 2011;29:977-988.
20. Marta-Pedroso C, Freitas H, Domingos T. Testing for the survey mode effect on contingent valuation data quality: A case study of web based versus in person interviews. Ecol Econ 2007;62:388-398.
21. Nielsen JS. Use of the internet for willingness-to-pay survey: A comparison of face-to-face and web-based interviews. Res Energy Econ 2011;33:119-129.
22. Orme BK. Getting started with conjoint analysis: strategies for product design and pricing research. Madison, WI: Research Publishers LLC; 2006.
23. Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Muhlbacher A, Regier DA, Bresnahan BW, Kanninen B, Bridges JF. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health 2013;16:3-13.
24. Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013;31:3800-3806.
25. El-Amm J, Freeman A, Patel N, Aragon-Ching JB. Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. Prostate Cancer 2013;2013:210686.
26. Lipton A, Balakumaran A. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletalrelated events in patients with solid tumors. Expert Rev Clin Pharmacol 2012;5:359-371.